Acticor Biotech, a clinical stage biotechnology company (raised on the basis of a work initiated in Team 6 of U1148) involved in the acute phase of thrombotic diseases, including stroke and myocardial infarction, today announced the agreement of Dutch Authorities for the initiation of a phase I clinical trial in healthy volunteers with its drug candidate, ACT017. ACT017 is a humanized fragment of monoclonal antibody (Fab) directed against a platelet glycoprotein (GPVI) involved in thrombosis.